PARIS, September 4, 2012 /PRNewswire/ --

The world's most potent antioxidant to date MitoQ^®, proven 1000 times stronger than CoQ^[10], will become available to the public this September 2012. MitoQ^® facial cream is set to challenge the international industry with a new level of efficacy

Dubbed next generation CoQ^[10], MitoQ^® is scientifically proven 1000 times more powerful in protecting skin cells from oxidative damage than idebenone or CoQ, both utilised extensively in the world's best selling anti-aging products. The September 2012 launch of MitoQ^® facial cream sets a new standard for those seeking rejuvenation, through science and skin health. The MitoQ^® molecule, the key ingredient in the MitoQ^® cream is a recognised and patented invention. It is the only product available that can penetrate mitochondrial membrane, where it delivers powerful antioxidant.

     (Photo: http://photos.prnewswire.com/prnh/20120904/559249 )

The major scientific breakthrough: the active potency of MitoQ^® to eliminate oxidative damage caused by free radicals, has been acknowledged by the highest scientific authorities. Studies and articles have been published in renowned scientific peer-reviewed journals, including: Annals of the New York Academy of Sciences^[1] and the Journal of Biological Chemistry.^[2]

Antipodean Pharmaceuticals CEO Dr Kenneth Taylor says: "We identified the breakthrough as being potentially huge amongst the globally aging population looking for aging solutions. Our topical skincare cream MitoQ^® accelerates the skin cells' natural renewal cycle, with rejuvenation evidenced in the outward skin brightening and a clearer more even complexion developing with the reduction of fine lines and fading any pigments. It's bio-tech at the beauty counter."

MitoQ^® facial cream is the result of over ten years of research and development with costs recorded at over $US30 million-to-date. It is the work of Dr Michael Murphy, Mitochondrial Biology Unit, Cambridge and Professor Rob Smith Chemistry Department, Otago University, New Zealand. In a cutting-edge development a unique electrostatic penetration system is used to deliver antioxidant to the cells mitochondria. Neutralising free radicals where they are produced. Thus, stopping the skin aging process and healing prior damage.

MitoQ^® re-densifies skin, healing and preventing fine lines and wrinkles. MitoQ^® fades scars, brown spots and skin discoloration. Preview users show impressive results as increased collagen re-formats and strengthens the skin's structure.

Real rejuvenation has become possible. With 20-year international patents in place there cannot be an over-the-counter product that uses this MitoQ^® exclusive technology in the foreseeable future.

Priced at (50ml) US$185 (approx €145) MitoQ^® facial cream will initially hit the global beauty market on http://www.MitoQ.com, this September  2012.

MitoQ^® is the world's most powerful antioxidant to date.

More information

About MitoQ Limited: Founded in 2005, MitoQ Limited, is a wholly owned New Zealand subsidiary of Antipodean Pharmaceuticals Inc, a development stage pharmaceutical company.

This dynamic bio-tech company works with a panel of experts to refine and bring to market breakthrough innovations, setting new standards in the pharmaceutical and cosmeceutical industries. CEO Kenneth Taylor has a doctorate in Pharmaceutical Chemistry and a Fellowship in Pharmacology and Experimental Therapeutics from The Johns Hopkins University School of Medicine, Baltimore, Maryland. He subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. During his professional career he held the position of Managing Director at various global Roche affiliates and converted Syntex into Roche Bioscience research centre.                                                                                                                              

Mr Gary Lane is the Chairman of the Board.

Notes

^[1] Smith, R.A.J. & Murphy, M. P. (2010). Animal and human studies with the mitochondria-targeted antioxidant MitoQ^®. Annals of the New YorkAcademy of Sciences. 1201, 96-103 doi: 10.111/j.1749-6632.2010.05627

^[2] James, A. M., Cochemé H.M., Smith, R.A.J. and  Murphy, M.P. (2005) Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species. The Journal of Biological Chemistry, 280 (22) 21295-21312. doi:10.1074/jbc.M501527200.

Website: http://www.mitoq.com

SOURCE MitoQ Limited